{"title":"格林-巴利综合征和慢性炎症性脱髓鞘性多发性神经病患者脑脊液腺苷-5'-三磷酸水平升高","authors":"Takamasa Nukui, Hideki Niimi, Tomohiro Hayashi, Nobuhiro Dougu, Mamoru Yamamoto, Ryoko Shibuya, Noriyuki Matsuda, Ryo Tanaka, Hiroaki Hirosawa, Risako Furuta, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Isao Kitajima, Yuji Nakatsuji","doi":"10.1155/2024/7229216","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Extracellular adenosine 5'-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity.</p><p><strong>Methods: </strong>CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs). In patients with CIDP, CSF ATP levels were compared before and after treatment. The correlations between CSF ATP levels and other factors, including clinical data and CSF protein levels, were also evaluated.</p><p><strong>Results: </strong>Median CSF ATP levels were significantly higher in patients with GBS and CIDP than in those with ONDs. When patients with CIDP were classified into two groups depending on their responsiveness to immunotherapy, median CSF ATP levels were significantly higher in good responders than in ONDs. CSF ATP levels tended to decrease after treatment in patients with CIDP. In patients with CIDP, there is a negative correlation between CSF ATP and CSF protein levels.</p><p><strong>Conclusions: </strong>CSF ATP levels were increased in patients with GBS and CIDP. In particular, CSF ATP levels tended to decrease following treatment in patients with CIDP. CSF ATP levels may be useful biomarkers for the diagnosis or monitoring of therapeutic effects in patients with GBS and CIDP.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182687/pdf/","citationCount":"0","resultStr":"{\"title\":\"Increased Cerebrospinal Fluid Adenosine 5'-Triphosphate Levels in Patients with Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.\",\"authors\":\"Takamasa Nukui, Hideki Niimi, Tomohiro Hayashi, Nobuhiro Dougu, Mamoru Yamamoto, Ryoko Shibuya, Noriyuki Matsuda, Ryo Tanaka, Hiroaki Hirosawa, Risako Furuta, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Isao Kitajima, Yuji Nakatsuji\",\"doi\":\"10.1155/2024/7229216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Extracellular adenosine 5'-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity.</p><p><strong>Methods: </strong>CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs). In patients with CIDP, CSF ATP levels were compared before and after treatment. The correlations between CSF ATP levels and other factors, including clinical data and CSF protein levels, were also evaluated.</p><p><strong>Results: </strong>Median CSF ATP levels were significantly higher in patients with GBS and CIDP than in those with ONDs. When patients with CIDP were classified into two groups depending on their responsiveness to immunotherapy, median CSF ATP levels were significantly higher in good responders than in ONDs. CSF ATP levels tended to decrease after treatment in patients with CIDP. In patients with CIDP, there is a negative correlation between CSF ATP and CSF protein levels.</p><p><strong>Conclusions: </strong>CSF ATP levels were increased in patients with GBS and CIDP. In particular, CSF ATP levels tended to decrease following treatment in patients with CIDP. CSF ATP levels may be useful biomarkers for the diagnosis or monitoring of therapeutic effects in patients with GBS and CIDP.</p>\",\"PeriodicalId\":19124,\"journal\":{\"name\":\"Neurology Research International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182687/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology Research International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/7229216\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Research International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/7229216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景：细胞外腺苷-5'-三磷酸（ATP）是周围神经的信号分子，可调节神经损伤后的髓鞘化。本研究探讨了吉兰-巴雷综合征（GBS）和慢性炎症性脱髓鞘性多发性神经病（CIDP）患者的脑脊液（CSF）ATP水平是否与疾病严重程度有关：将13名格林-巴利综合征（GBS）患者和18名CIDP患者的脑脊液ATP水平与16名其他神经系统疾病（OND）对照组患者的脑脊液ATP水平进行比较。在 CIDP 患者中，对治疗前后的 CSF ATP 水平进行了比较。研究还评估了 CSF ATP 水平与其他因素（包括临床数据和 CSF 蛋白水平）之间的相关性：结果：GBS 和 CIDP 患者的 CSF ATP 水平中位数明显高于 OND 患者。根据对免疫疗法的反应程度将CIDP患者分为两组，反应良好者的CSF ATP中位数水平明显高于OND患者。CIDP患者的脑脊液ATP水平在治疗后趋于下降。在CIDP患者中，CSF ATP与CSF蛋白水平呈负相关：结论：GBS 和 CIDP 患者的脑脊液 ATP 水平升高。结论：GBS 和 CIDP 患者的脑脊液 ATP 水平升高，尤其是 CIDP 患者在接受治疗后，脑脊液 ATP 水平呈下降趋势。CSF ATP水平可能是诊断或监测GBS和CIDP患者治疗效果的有用生物标志物。
Increased Cerebrospinal Fluid Adenosine 5'-Triphosphate Levels in Patients with Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.
Background: Extracellular adenosine 5'-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity.
Methods: CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs). In patients with CIDP, CSF ATP levels were compared before and after treatment. The correlations between CSF ATP levels and other factors, including clinical data and CSF protein levels, were also evaluated.
Results: Median CSF ATP levels were significantly higher in patients with GBS and CIDP than in those with ONDs. When patients with CIDP were classified into two groups depending on their responsiveness to immunotherapy, median CSF ATP levels were significantly higher in good responders than in ONDs. CSF ATP levels tended to decrease after treatment in patients with CIDP. In patients with CIDP, there is a negative correlation between CSF ATP and CSF protein levels.
Conclusions: CSF ATP levels were increased in patients with GBS and CIDP. In particular, CSF ATP levels tended to decrease following treatment in patients with CIDP. CSF ATP levels may be useful biomarkers for the diagnosis or monitoring of therapeutic effects in patients with GBS and CIDP.
期刊介绍：
Neurology Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on diseases of the nervous system, as well as normal neurological functioning. The journal will consider basic, translational, and clinical research, including animal models and clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
